Efficient adenovirus-mediated gene transfer into primary T cells and thymocytes in a new coxsackie/adenovirus receptor transgenic model by Hurez, Vincent et al.
BioMed  Central
Page 1 of 14
(page number not for citation purposes)
BMC Immunology
BMC Immunology  2002,  3 x Methodology article
Efficient adenovirus-mediated gene transfer into primary T cells 
and thymocytes in a new coxsackie/adenovirus receptor transgenic 
model
Vincent Hurez†1, Robin Dzialo-Hatton†1, James Oliver1, R James Matthews2 
and Casey T Weaver*1
Address: 1Department of Pathology, University of Alabama at Birmingham, Birmingham, AL 35294-2170, USA and 2Department of Medicine, 
University of Wales College of Medicine, Cardiff, CF4 CXX, UK
E-mail: Vincent Hurez - vhurez@uab.edu; Robin Dzialo-Hatton - rdzialo@path.uab.edu; James Oliver - joliver@path.uab.edu; R 
James Matthews - MatthewsRJ@Cardiff.ac.uk; Casey T Weaver* - cweaver@path.uab.edu
*Corresponding author      †Equal contributors
Abstract
Background: Gene transfer studies in primary T cells have suffered from the limitations of
conventional viral transduction or transfection techniques. Replication-defective adenoviral vectors
are an attractive alternative for gene delivery. However, naive lymphocytes are not readily
susceptible to infection with adenoviruses due to insufficient expression of the coxsackie/
adenovirus receptor.
Results: To render T cells susceptible to adenoviral gene transfer, we have developed three new
murine transgenic lines in which expression of the human coxsackie/adenovirus receptor (hCAR)
with a truncated cytoplasmic domain (hCAR∆ cyt) is limited to thymocytes and lymphocytes under
direction of a human CD2 mini-gene. hCAR∆ cyt.CD2 transgenic mice were crossed with DO11.10
T cell receptor transgenic mice (DO11.hCAR∆ cyt) to allow developmental studies in a defined,
clonal T cell population. Expression of hCAR∆ cyt enabled adenoviral transduction of resting
primary CD4+ T cells, differentiated effector T cells and thymocytes from DO11.hCAR∆ cyt with
high efficiency. Expression of hCAR∆ cyt transgene did not perturb T cell development in these
mice and adenoviral transduction of DO11.hCAR∆ cyt T cells did not alter their activation status,
functional responses or differentiative potential. Adoptive transfer of the transduced T cells into
normal recipients did not modify their physiologic localization.
Conclusion: The DO11.hCAR∆ cyt transgenic model thus allows efficient gene transfer in primary
T cell populations and will be valuable for novel studies of T cell activation and differentiation.
Background
Gene transfer into developing and mature primary T cells
has been limited by the lack of efficient techniques for ex
vivo or in vivo transfection or transduction. The adapta-
tion of retroviral vectors for gene delivery into lym-
phocytes has gained favor recently [1,2], but has several
features that limit its use. First, retroviral gene transduc-
tion requires cell cycle progression of the cellular host to
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permit viral genome integration, limiting studies of regu-
latory genes that are operative early in T cell activation or
differentiation. Second, because the integration site of the
viral genome is variable, there can be local, host chroma-
tin effects on exogenous gene expression and unpredicta-
ble silencing of viral integrants. Third, efficiencies of
transduction with retroviral vectors are often limiting. Fi-
nally, the retroviral genome is small, limiting the size of
exogenous genes that can be packaged.
Replication-defective adenoviral vectors offer several ad-
vantages that make them attractive for gene delivery [3–
6]. Adenoviral vectors are able to transduce proliferating
or quiescent cells; they can accommodate dual, large in-
sert sizes and can deliver additional genes by superinfec-
tion; and stable, high-titer viral stocks are easily generated
[7]. Further, since the adenoviral genome is maintained
extra-chromosomally, insertion site-dependent effects of
the host genome are minimized, and exogenous genes can
be reliably expressed at high levels. Unfortunately, naive
lymphocytes are not susceptible to infection with adeno-
viruses due to lack of detectable expression of a viral re-
ceptor, such as the coxsackie/adenovirus receptor (CAR),
which is required for efficient viral attachment [8–10].
The CAR protein contains two extra-cellular immu-
noglobulin-like (Ig) domains, the first of which appears
sufficient for binding to the adenoviral fiber knob protein
[11,12]. Expression of either human or murine CAR in
various cell lines has been shown to facilitate gene transfer
by recombinant human adenoviruses [8–10,13]. Stable
transfection of transformed murine B and T cells lines
with human CAR (hCAR) lacking its cytoplasmic domain
rendered them susceptible to adenoviral transfection, es-
tablishing that lymphoid cells can be permissive hosts for
adenoviral transduction and demonstrating that the cyto-
plasmic domain of CAR is not required for viral entry
[13]. More recently, mice transgenic for full length [14] or
truncated hCAR [15] have been described in which aden-
oviral transduction of primary lymphocytes has been
demonstrated.
We describe here three new transgenic (Tg) mouse lines in
which expression of human CAR with a truncated cyto-
plasmic domain (hCAR∆ cyt) is limited to thymocytes and
lymphocytes under direction of a human CD2 mini-gene
[16]. The three lines are similar in having transgene ex-
pression restricted to the lymphoid lineage, but differ in
the pattern of hCAR∆ cyt expression profiles within lym-
phoid populations. In each transgenic line, expression of
the hCAR∆ cyt transgene imparted susceptibility to effi-
cient adenoviral transduction that was independent of cel-
lular activation. By crossing the hCAR∆ cyt.CD2 Tg mice
with DO11.10 TCR Tg mice, we have generated an anti-
gen-specific model with which to study the effects of ade-
novirally delivered genes on T cell activation and
differentiation. Transduction of hCAR∆ cyt-positive naïve,
Th1 or Th2 DO11.10 T cells with a recombinant adenovi-
ral vector resulted in high-level reporter gene expression
without detectable activation of transduced cells or dele-
terious effect on their antigenic responses.
Results
hCAR∆ cyt.CD2 transgenic mice: characterization of dis-
tinct hCAR expression profiles in three different founder 
lines
To develop a transgenic model with high-level expression
of hCAR on murine T cells, a transgene was constructed
based on a human CD2 mini-gene described previously
[16] (Fig. 1A). This mini-gene includes the 5' promoter re-
gion of the hCD2 gene as well as the hCD2 LCR, which is
reported to direct transgene expression to T cells in a posi-
tion-independent, copy number-dependent manner
[17,18]. Since the function of CAR is undefined, and dele-
tion of the cytoplasmic tail of hCAR does not adversely af-
fect adenoviral transduction [13,19], a cDNA encoding a
cytoplasmic tail-truncated variant of hCAR (hCAR∆ cyt)
was generated and inserted into the CD2 mini-gene to
eliminate any potential signaling capacity of hCAR. Of
eight founder mice bearing an intact transgene, all dem-
onstrated lymphoid lineage-specific expression of
hCAR∆ cyt, with three distinct expression profiles repre-
sented by founder lines 6, 13, and 18 (Figure 1B and data
not shown). To develop an antigen-specific T cell system
with which to deliver genes of interest, each of these lines
was then crossed with DO11.10 TCR Tg mice [20] to gen-
erate the DO11.hCAR∆ cyt double transgenic lines shown
(Figure 1B & 1C).
Lymph node cells were isolated from mice in
DO11.hCAR∆ cyt lines 6, 13 and 18, stained with antibod-
ies to CD4, CD8, CD19 and RmcB (anti-hCAR) and ana-
lyzed by flow cytometry (Fig. 1B). All of the CD4+ and
CD8+ T cells from line 6 and 18 expressed high levels of
the hCAR∆ cyt transgene, while CD4+ and CD8+T cells
from line 13 had a bimodal pattern of expression, with
approximately 35% of both CD4+ and CD8+ negative for
hCAR∆ cyt. While both lines 13 and 18 had negligible ex-
pression in the B cell compartment, the vast majority of B
cells from line 6 expressed the hCAR∆ cyt transgene, al-
though at a lower level than the T cells (mean fluorescence
intensity (MFI): CD19+ B cells, 64; CD4+ T cells, 193).
hCAR∆ cyt was not detected in non-lymphoid tissues nor
on lymphocytes from non-transgenic littermate controls
(data not shown).
To determine at what developmental stage the hCAR∆ cyt
transgene is expressed in T cells, thymocytes were isolated
from 4-week-old mice and the expression of hCAR∆ cyt
relative to the expression of CD4 and CD8 was evaluated
(Fig. 1C). Consistent with the expression of hCAR∆ cyt onBMC Immunology 2002, 3 http://www.biomedcentral.com/1471-2172/3/4
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Figure 1
hCAR∆ cyt transgene map and expression in lymph node cells and thymocytes of hCAR transgenic mice.A. An
807 bp fragment (hatched box) encoding the extracellular and transmembrane region with a truncated cytoplasmic tail (TM-
RKKKRR*) of the human CAR was cloned into the EcoRI/SmaI site of VA hCD2. The hCAR∆ cyt coding region was inserted
between intron 1 of hCD2 and the poly A1 site from the hCD2 3' untranslated region. All potential ATG start codons in exon
1 of hCD2 have been mutated [16]. B. Lymphoid cells were isolated from three different transgenic lines (6, 13 and 18) and
stained with RmcB anti-human CAR mAb and anti-mouse CD4, CD8 or CD19 before analysis on a FACSscan. The quadrants
were set based on the staining of a hCAR∆ cyt negative littermate control (data not shown). The graphs represent two-color
dot plots of lymph node cells gated on viable lymphoid gate; the percentage of cells in each quadrant is indicated. C. Two-color
dot plots of thymocytes stained with anti-CD4 and anti-CD8 mAbs. The staining with the anti-hCAR RmcB mAb is repre-
sented as a histogram for each corresponding quadrant with the percentage of positive cells.
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mature CD4+ and CD8+ T cells from lines 6 and 18, all of
the thymocytes in the CD4+CD8+ double positive (DP)
and CD4+ or CD8+ single positive (SP) fractions were pos-
itive for hCAR∆ cyt. In line 13, approximately 68% of the
DP and SP cells expressed hCAR∆ cyt, consistent with the
expression of hCAR∆ cyt on T cells in the periphery. A low-
er percentage of hCAR∆ cyt positive cells was observed in
the CD4-CD8- double negative fraction in all lines stud-
ied, which likely reflects the heterogeneous nature of the
double negative population. The skewed pattern of thy-
mocyte development toward CD4+ single positive in each
of the lines was similar to that observed in
DO11.10.hCAR∆ cyt- control littermates (data not
shown). Thus, in the three distinct lines studied, the CD2
promoter/LCR/enhancer directed the expression of the
hCAR∆ cyt transgene to the T cell and in one of the lines,
the B cell lineage. Line 18 was chosen for further study as
the recipient of adenoviral-mediated gene delivery due to
its uniform, T cell-specific expression of the hCAR∆ cyt
transgene.
Primary T cells and thymocytes from DO11.hCAR∆ cyt 
mice are efficiently transduced by adenoviral vectors
To determine whether lymphocytes from hCAR∆ cyt.CD2
transgenic mice were susceptible to adenoviral transduc-
tion, lymph node cells were isolated from line
DO11.hCAR∆ cyt.18 and incubated with adenoviral vec-
tors designed to express GFP under the control of the
CMV5 or ubiquitin (UbP) promoters (Fig. 2A). Seventy
percent of resting CD4+ cells that were transduced with
the Ad5.UbP.GFP expressed the GFP reporter without ac-
tivation. In contrast, only 36% of resting CD4+ cells trans-
duced with the Ad5.CMV5.GFP were GFP+, and the mean
fluorescence intensity was lower, suggesting an inability
of the CMV5 promoter to induce strong GFP expression in
resting T cells. Following activation with PMA and iono-
mycin, CMV5-driven expression of GFP increased to 81%
of the CD4+ T cells. A small percentage of CD4- cells, rep-
resenting the hCAR∆ cyt+ CD8+ fraction, were transduced
with both the UbP and CMV5 viruses as well.
To determine whether adenoviral transduction changed
their activation status, resting CD4+ T cells were examined
for expression of the early activation markers CD62L (L-
selectin) and CD25 (IL-2Rα ). After transduction with
Ad5.UbP.GFP or Ad5.CMV5.GFP without PMA/ionomy-
cin, the GFP positive and the GFP negative fractions of
CD4+ cells were both CD62L high and CD25 low, con-
firming that the cells were initially of a resting phenotype
and that adenoviral transduction did not activate them.
Upon activation with PMA/ionomycin, the CD4+ T cells
down-regulated CD62L and up-regulated CD25 (Fig. 2A).
Control T cells from hCAR∆ cyt transgene-negative litter-
mates had indistinguishable flow cytometric profile (data
not shown).
Because the expression of hCAR∆ cyt was detected early in
thymocyte development (Fig. 1C), the ability of these cells
to be transduced by adenovirus was also determined. Thy-
mocytes from line 18 were incubated with Ad5.UbP.GFP
as stated above, and were evaluated by flow cytometry for
their expression of CD4, CD8, and GFP (Fig. 2B). Seventy-
five percent of the CD4 SP cells were transduced for GFP
expression, consistent with the transduction frequency of
CD4+ T cells in the periphery. Approximately half of the
CD8 SP could be transduced as well. Interestingly, where-
as a high percentage of the DN thymocytes expressed GFP
after transduction (75%), the DP fraction was relatively
refractory to transduction even though all of the DP cells
expressed hCAR∆ cyt; less than 10% of the transduced DP
cells were GFP-positive irrespective of the MOI tested (Fig.
2B and data not shown).
Adenoviral transduction of Th1 and Th2 lines derived from 
DO11.hCAR∆ cyt transgenic mice
To examine the susceptibility of effector T cell populations
to adenoviral transduction, Th1 and Th2 cells were de-
rived from DO11.hCAR∆ cyt.18 mice by in vitro culture
under polarizing cytokine conditions [21]. The resulting
Th1 and Th2 lines were incubated with Ad5.UbP.GFP or
Ad5.CMV5.GFP, with or without activation with PMA/
ionomycin, and expression of GFP was measured by flow
cytometry 24 hours later (Fig. 3 and Table 1). Similar to
naïve T cells, resting Th1 and Th2 cells were readily trans-
duced by Ad5.UbP.GFP, and PMA/ionomycin activation
had little effect on either the frequency or expression lev-
els of GFP positive cells. In contrast, both the frequencies
and levels of GFP expression were increased in
Ad5.CMV5.GFP-transduced Th1 and Th2 lines following
activation with PMA/ionomycin, anti-CD3 or OVA pep-
tide. Further, the activation-induced expression of GFP by
cells transduced with the Ad5.CMV5 vector yielded signif-
icantly better expression levels than those induced by the
Ad5.UbP vector. Thus, both Th1 and Th2 effectors derived
from DO11.hCAR∆ cyt mice are competent hosts for ade-
noviral transduction, and were equivalent to or better
than naïve DO11.hCAR∆ cyt cells with respect to their
transduction efficiencies and/or reporter expression lev-
els.
Adenoviral transduction does not alter the functional re-
sponses or differentiative potential of primary T cells
Although adenoviral transduction did not induce detecta-
ble activation of resting, naïve CD4+ T cells (Figure 2), we
wished to further determine whether transduction altered
the activation-induced functions of this population. The
proliferative responses and potential for Th1 and Th2
phenotype development were therefore examined follow-
ing adenoviral transduction. CD4+ T cells isolated from
DO11.hCAR∆ cyt.18 mice were transduced with
Ad5.UbP.GFP, and were sorted after 24 hours based onBMC Immunology 2002, 3 http://www.biomedcentral.com/1471-2172/3/4
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Figure 2
Transduction with Ad5.UbP.GFP and Ad5.CMV5.GFP of lymph node cells and thymocytes from line 18 mice.
Lymph node cells and thymocytes from line 18 mice were isolated and transduced with Ad5.UbP.GFP or Ad5.CMV5.GFP ade-
noviral reporter vectors at a MOI of 10 for 30' and incubated for 24 h at 37°C/5%CO2. Half of the cells transduced with
Ad5.CMV5.GFP were stimulated for 4 h with PMA/ionomycin before analysis. Lymph node cells were then stained with anti-
CD4, anti-CD25 and anti-CD62L; thymocytes were stained with anti-CD4 and anti-CD8. The quadrants were set based on the
transduction of hCAR∆ cyt negative littermate controls (data not shown). A. Two color dot-plots of lymph nodes cells trans-
duced with Ad5.Ubp.GFP or Ad5.CMV5.GFP with or without activation with PMA/ionomycin. The top panel represent the
expression of hCAR∆ cyt and CD4 detected in the viable lymphoid gate while the two bottom panel were gated on CD4 posi-
tive cells only (rectangular gate). The percentage of cells in each quadrant is indicated. B. Two-color dot plot of CD4 and CD8
expression of line 18 thymocytes transduced with Ad5.UbP.GFP. The histograms represent the GFP expression for each thy-
mocyte subset defined by their CD4 and CD8 expression. The percentage of GFP positive cells is indicated.
1% 1%
67%
15% 35%
5%
100
101
102
103
104
100
101
102
103
104
100 101 102 103 104
25% 66%
5%
28% 16%
1%
56% 29%
3%
9% 39%
3%
0% 1%
81%
9% 6%
33%
18% 71%
8%
100 101 102 103 104100 101 102 103 104
100
101
102
103
104
CD4+ CD4+
Ad5.UbP.GFP Ad5.CMV5.GFP
Ad5.CMV5.GFP
+ PMA/Ion A.
8.3%
75%
52%
75%
B.
C
D
8
C
D
2
5
C
D
6
2
L
C
D
4
GFP
100 101 102 103 104 100 101 102 103 104 100 101 102 103
101
102
103
104
GFP CD4 GFP
2% 69%
27% 2%
CD4+BMC Immunology 2002, 3 http://www.biomedcentral.com/1471-2172/3/4
Page 6 of 14
(page number not for citation purposes)
their expression of GFP. The sorted cells were cultured
with antigen presenting cells and increasing concentra-
tions of OVA peptide for 3 days and then pulsed with
[3H]thymidine for 24 hours. Figure 4A shows that the GFP
positive population of Ad-transduced cells had a compa-
rable proliferative response to the non-transduced GFP
negative cells across the entire antigen dose range. Thus,
adenoviral transduction did not significantly affect prima-
ry CD4 T cell proliferation.
Transduced, sorted GFP+ and GFP- CD4 T cells were cul-
tured under Th1-/Th2-polarizing conditions and exam-
ined for cytokine production following re-stimulation to
determine potential effects of adenoviral transduction on
effector phenotype development (Figure 4B). Following
one week of polarization, Th1 and Th2 cells were tested by
ELISA for their ability to produce cytokines indicative of
the two different T cell subsets (Figure 4B). Th1- and Th2-
polarized cells from both the transduced (GFP+) and non-
transduced (GFP-) populations produced comparable
amounts of Th1-specific (IFN-γ ) or Th2-specific (IL-4 and
IL-10) cytokines, respectively. Cytokine production by
Th1- and Th2-polarized DO11.10 T cells from hCAR∆ cyt-
negative littermate controls was not significantly different
Figure 3
Transduction with Ad5.UbP.GFP and Ad5.CMV5.GFP of Th1 and Th2 lines derived from line 18 mice. Th1 and
Th2 lines were derived from line 18 DO11.hCAR∆ cyt double transgenic mice by antigenic stimulation in polarizing conditions
for 3 weeks. One week after the last antigenic stimulation, the resting Th1 and Th2 lines were transduced for 30' with
Ad5.UbP.GFP or Ad5.CMV5.GFP at a MOI of 4 and incubated for 24 h at 37°C/5%CO2. Half of the cells transduced with
Ad5.CMV5.GFP were stimulated for 4 h with PMA/ionomycin before analysis. The histograms represent the GFP expression of
the Th1 (left panels) and Th2 (right panels) lines transduced with the indicated adenovirus with or without stimulation with
PMA/ionomycin. The percentage of positive cells and mean fluorescence intensity are indicated in Table 1.
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(data not shown). Thus, neither hCAR expression nor ad-
enoviral transduction alters the naïve T cell's potential for
Th1 or Th2 phenotype development.
In vivo trafficking of Ad-transduced CD4+ T cells
To further investigate the effects of adenoviral transduc-
tion on T cell biology, and to examine the possibility that
hCAR expression (an Ig superfamily member of undeter-
mined function) might alter the in vivo distribution of
transduced T cells, we examined the tissue distribution of
DO11.hCAR∆ cyt T cells following adoptive transfer into
BALB/c recipients. For these experiments, we used line 13
DO11.hCAR∆ cyt Tg mice that have a bimodal distribu-
tion of hCAR expression to provide an internal control,
"sham transfection" population. CD4+ cells were isolated
from DO11.hCAR∆ cyt.13 lymph and spleen cells and
transduced with Ad5.UbP.GFP. Twenty-four hours later,
transduced T cells were recovered and examined for GFP
expression by flow cytometry prior to transfer of 5 ×  106
cells into each recipient mouse. In a representative exper-
iment shown in Figure 5, 45% percent of the pre-transfer
CD4+ cells expressed the clonotypic marker KJ-126 and of
these cells, 47.5% had been transduced for GFP expres-
sion (Fig. 5A, top panel).
Forty-eight hours after I.V. injection of the transduced
(DO11.hCAR∆ cyt.13) or control (DO11.10) cells, recipi-
ent mice were sacrificed and secondary lymphoid tissues
(lymph nodes, spleen and Peyer's patches) were divided
for detection of the transferred KJ1-26+ and GFP+ T cells
by flow cytometry (Fig. 5A, lower panel) or immuno-his-
tochemistry (Fig. 5B). Flow cytometric analysis deter-
mined that the transferred population of Ad-transduced
cells from DO11.hCAR∆ cyt Tg donors retained the pre-
transfer frequencies of GFP+ and GFP- cells within the
DO11.10 T cell (CD4+KJ1-26+) fraction and were equiva-
lent to control DO11.10 cells with respect to the relative
distribution between secondary lymphoid organs (Fig. 5A
& 5B; data not shown). Thus, 51.5% of the recovered KJ1-
26 positive cells isolated from pooled lymph nodes ex-
pressed GFP, compared to a pre-transfer frequency of
47.5%. Similar results were obtained in recovered splenic
tissues, and at 72 and 96 hours post-transfer (data not
shown). There was an increase in the level of GFP reporter
expression by Ad-transduced cells in the interval between
transfer and recovery (pre-transfer MFI: 75; post-transfer
MFI: 320), suggesting continued GFP transcription in vi-
vo. Thus, there was no preferential loss or increase of the
Ad-transduced cells in vivo, nor were there gross differenc-
es in trafficking to secondary lymphoid tissues.
To determine if adenoviral transduction or GFP reporter
expression altered T cell trafficking to tissue microenvi-
ronments, recovered lymphoid tissues were sectioned and
processed for fluorescent microscopic analysis (Figure 5B
and Table 2). A double-label immunofluorescent proto-
col was developed to permit in situ localization of GFP+
or KJ1-26+ T cells and B220+ B cells in fixed, frozen tissue
sections (Figure 5B, and data not shown). Irrespective of
the population of T cells transferred (DO11.10 wild-type
control or Ad5.UbC.GFP-transduced DO11.hCAR∆ cyt), a
similar distribution of KJ1-26+ and GFP+ T cells was found
within the secondary lymphoid tissue microenviron-
ments. In the spleen, KJ1-26+ or GFP+ cells were primarily
located within the periarterial lymphoid sheaths (PALS),
with fewer positive cells in the marginal zones, and only
scattered positive cells in the red pulp (Table 2). Relatively
few positive cells were detected within the B cell follicles,
although positive cells could be found in the PALS, at the
border with B cell follicles. Similarly, in lymph nodes and
Peyer's patches, the wild-type and Ad-transduced trans-
genic T cells localized primarily to paracortical T cell areas.
Collectively, these data indicate that neither hCAR∆ cyt or
GFP expression nor adenoviral transduction affects surviv-
Table 1: Transduction of Th1 and Th2 lines with Ad5.CMV5.GFP and Ad5.UbP.GFP
Stimulation*
T cell Line/Ad Vector None Anti-CD3 OVA peptide PMA/Ionomycin
Th1+Ad5.UbP.GFP 51% (117)a NDb ND 54% (139)
Th1+Ad5.CMV5.GFP 20% (112) 27% (212) 45% (529) 73% (1122)
Th2+Ad5.UbP.GFP 60% (212) ND ND 70% (269)
Th2+Ad5.CMV5.GFP 43% (242) 66% (1274) 70% (753) 75% (1421)
*Th1 and Th2 lines derived from line 18 DO11.10/hCAR∆ cyt transgenic mice were transduced and GFP expression was analyzed as described in 
Fig. 4. The lines were activated by incubation on anti-CD3 coated plates (10 µg/ml), addition of irradiated BALB/c splenocytes and 5 µg/ml of OVA 
peptide or 50 ng/ml PMA and 5 µM ionomycin for 24 h at 37°C/5% CO2. aPercentage of GFP positive cells (and mean fluorescence intensity of the 
GFP positive population) are indicated. bND – not determined.BMC Immunology 2002, 3 http://www.biomedcentral.com/1471-2172/3/4
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al or trafficking of adoptively transferred cells for at least
4 days in vivo.
Discussion
The introduction of transgenic systems adapted to take ad-
vantage of adenoviral gene delivery technology offers an
attractive adjunct to existing gene delivery strategies for
studies of lymphocyte biology. In an effort to facilitate
gene transfer into primary lymphocytes, we and others
[14,15] have employed different strategies to engineer
transgenic mice that express the human adenoviral recep-
tor, hCAR, on murine lymphocytes. Here we report the
characterization of three new transgenic lines that express
a cytoplasmic-tail truncated hCAR under control of hCD2
gene regulatory elements, and demonstrate their utility for
gene transfer studies of primary T cells and thymocytes. In
agreement with previous studies using human CD2 mini-
gene expression cassette [16–18], the truncated hCAR
transgene was expressed in all cells of the T cell lineage,
and except for transgenic line 6 (hCAR∆ cyt.CD2.6), in
which there was expression on mature B cells as well as T
cells, hCAR was not expressed by non-T cells. Importantly,
the expression of hCAR∆ cyt by T cells was stable and high-
level at all stages of development, from double-negative
thymocytes to Th1 and Th2 effectors. With the possible
exception of double positive thymocytes (see below), re-
porter expression by transduced hCAR∆ cyt-positive cells
at each of these developmental stages was very efficient.
Thus, it is possible to target adenoviral transduction to the
T cell compartment in vitro and in vivo. Of particular
note, the level of expression of hCAR∆ cyt was not signifi-
cantly lower for double-negative and double-positive thy-
mocyte populations in line hCAR∆ cyt.CD2.18 mice,
contrary to what was observed previously [15]. The high-
level expression of hCAR∆ cyt by double-negative (CD4-
CD8-) thymocytes rendered this population readily trans-
ducible, suggesting that these early thymocytes express
sufficient integrin co-receptors (e.g. α vβ 3 or α vβ 5) for ad-
enoviral entry and making this a useful model for early
thymocyte gene targeting
Despite expression of levels of hCAR∆ cyt comparable to
that of double-negative and single-positive thymocytes,
double-positive thymocytes were relatively refractory to
reporter expression following transduction with either the
Ad5.UbP.GFP or Ad5.CMV5.GFP vector. The lack of re-
porter expression could reflect poor entry of adenovirus in
this population or poor transcriptional activity of the pro-
moters used (UbP and CMV5), among other possibilites.
Given the comparable levels of hCAR∆ cyt expression by
double-positive and double-negative or single positive
thymocytes, it is unlikely that viral entry is limiting in
these cells, although this has not been formally tested. We
favor the possibility that the poor reporter expression re-
flects inefficient transcriptional activity of these promot-
Figure 4
Transduction of CD4+ T cells from line 18 mice does
not affect proliferation or cytokine production. CD4+
T cells were isolated from spleen and lymph nodes of line
DO11.hCAR∆ cyt.18 double transgenic mice, transduced for
30' with Ad5.UbP.GFP at a MOI of 10 and incubated for 24 h
at 37°C/5%CO2. The GFP positive and GFP negative popula-
tion were then sorted on a FACSvantage cell sorter before
assay. A. Proliferative responses of the GFP- and GFP+ pop-
ulation stimulated for 72 h with increasing amount of OVA
peptide in the presence of irradiated BALB/c splenocytes. 50
µCi/ml [3H]thymidine was added to the cultures for 48 h
before harvesting the cells and count of the incorporated
radioactivity. The curves represent the dose-dependant pro-
liferative responses (as indicated by the [3H]thymidine incor-
poration in CPM) of the GFP+ (closed circles) and the GFP-
(open diamond) populations. B. Cytokine production of the
transduced CD4+ cells. The GFP+ and GFP- sorted popula-
tion were stimulated with irradiated BALB/c splenocytes and
5 µg/ml ovalbumin peptide in conditions driving them toward
a Th1 or a Th2 phenotype. One week later, the culture
supernatant were collected and analyzed by ELISA for the
production of IFN-γ , IL-4 and IL-10. The histogram indicates
the concentration of the different cytokines produced by the
indicated populations. The relative concentrations were cal-
culated using serial dilution of a known standard for each
cytokine as a reference curve.
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Figure 5
Adoptive transfer of CD4+ T cells from line 18 mice in BALB/c recipient. CD4+ T cells were isolated from spleen
and lymph nodes of DO11.hCAR∆ cyt line 13 transgenic mice, transduced for 30' with Ad5.UbP.GFP at a MOI of 10 and incu-
bated for 24 h at 37°C/5%CO2. 5 ×  106 transduced cells were injected in the tail vein of BALB/c mice. The mice were sacrificed
after 48 h and the inguinal, axillary, submandibular and mesenteric lymph nodes, the spleen and the Peyer's Patches were iso-
lated. A. Flow cytometric analysis of GFP expression of transduced CD4+ cells before and after adoptive transfer. Recovered,
pooled lymph node cells from BALB/c recipients were stained with anti-CD4 and anti-DO11.10 TCR clonotypic mAb, KJ-126,
and analyzed on a FACScan. The panels depict two-color dot plots of the transduced CD4+ cells before transfer (top panel)
and the pooled lymph node cells from a representative BALB/c recipient (lower panel) and histograms representing the GFP
expression for each of the CD4+KJ126+ population (square gate). The percentage of positive cells is indicated. B. Immunohis-
tochemical analysis of a peripheral lymph node of Ad5.UbP.GFP-transduced CD4 T cell adoptive transfer recipient. An inguinal
lymph node was processed and stained with anti-B22O (red) as described in Material and Methods. The red fluorescent areas
define primary B cell follicles. GFP positive cells (green) are indicated (arrows) in parafollicular, T cell areas of a representative
lymph node (magnification: top, 10× ; bottom, 40× ).BMC Immunology 2002, 3 http://www.biomedcentral.com/1471-2172/3/4
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ers at this developmental stage. In this same vein,
expression of the GFP reporter by freshly isolated mature
T cells transduced with the Ad5.UbP.GFP vector was very
efficient, while the Ad5.CMV5.GFP vector required a post-
transduction activation of T cells to induce optimal ex-
pression of GFP [14,15]. On the contrary, the CMV5 pro-
moter yielded better reporter expression in activated,
transduced Th1 and Th2 cells. Thus, the choice of promot-
er will need to be optimized for each adenoviral vector de-
pending on the developmental stage and specific purpose
for its use. Studies with other promoter elements (e.g.
CD2) are in progress and should be informative.
Interestingly, the bimodal pattern of transgene expression
by T cells and thymocytes from line hCAR∆ cyt.CD2.13
suggested some positional effect variegation (PEV) of the
transgene, an effect not previously reported in trangenes
that include the entire CD2 LCR [17,18]. Further, we have
noticed that the percentage of hCAR∆ cyt positive T cells in
the line hCAR∆ cyt.CD2.13 increased with successive gen-
erations of back-cross of the original hCAR∆ cyt founder
(B6xSJL F1) onto a BALB/c background, reflecting a strain
background effect of the PEV (data not shown). Although
the mechanism of this expression heterogeneity is not
clear, it is fortuitous in providing different lines that offer
distinct targeting profiles. Accordingly, it should prove
possible to target both B and T cells in line hCAR∆
cyt.CD2.6 mice, whereas line hCAR∆ cyt.CD2.13 mice can
be exploited to perform transduction studies in which
there is an hCAR∆ cyt negative population to serve as an
internal control (Figure 5).
An important consideration at the outset of these studies
concerned the possibility that ectopic hCAR expression or
adenoviral transduction might affect the normal develop-
ment and/or function of T cells. For this reason, we chose
to use a truncated variant of hCAR to preclude possible
signaling by this molecule [13]. As evidenced by the func-
tional data reported herein, and those from previous re-
ports [14,15], there does not appear to be an adverse effect
of either hCAR∆ cyt expression or adenoviral transduction
on T cell activation, development or function. The anti-
gen-induced proliferative responses of naïve
DO11.hCAR∆ cyt T cells were comparable to those of non-
hCAR DO11.10 littermates, and the differentiative poten-
tial of transduced naïve T cells into Th1 or Th2 effectors
was not compromised. While at higher multiplicities of
adenoviral infection (MOIs) than those required for effi-
cient transduction there were deleterious effects on naïve
T cell viability (data not shown), at the MOIs used we saw
no decrease in cell viability or function. Further, adenovi-
ral transduction of resting, naïve T cells exerted no detect-
Table 2: Anatomic Distribution of Ad5.UbP.GFP-transduced DO11.hCAR∆ cyt versus Control DO11.10 T Cell Populations following 
Adoptive Transfer
% of Total KJ1-26+ Cells in Each Lymphoid Tissue Microenvironmenta
Tissue/Microenvironent DO11.10 GFP-positive DO11.hCAR∆ cyt
Spleen
PALS 92b 91
Primary Nodules/Follicles 3 5
Marginal Zone 4 2
Red Pulp 1 3
Inguinal LN
Diffuse Cortex/Paracortex 98 97
Primary Nodules/Follicles 2 3
Medullary Cords 0 0
Mesenteric LN
Diffuse Cortex/Paracortex 97 96
Primary Nodules/Follicles 3 4
Medullary Cords 0 0
Peyer's Patch
Paranodular zones (T cell) 99 98
Nodules (B cell) 1 2
a Two days following transfer of 5 ×  106 DO11.10 or Ad5.UbP.GFP-transduced DO11.hCAR∆ cyt CD4+ T cells into BALB/c recipients, animals 
were sacrificed and the recovered lymphoid tissues were processed for microscopic analysis as described in Material and Methods. b Numbers are 
the fraction of the total cell population in each tissue. Definition of the lymphoid tissue microenvironments follows the nomenclature of Weiss. 
Data are the mean from 3–4 animals per group (standard deviations <16%).BMC Immunology 2002, 3 http://www.biomedcentral.com/1471-2172/3/4
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able intrinsic activation of these cells, suggesting that
adenoviral delivery of genes of interest to non-cycling T
cells will permit loss or gain of function studies prior to
antigen- or mitogen-driven stimulation.
Ad-transduced DO11.hCAR∆ cyt trafficked normally to
secondary lymphoid organs following adoptive transfer,
indicating that neither hCAR∆ cyt nor adenoviral trans-
duction altered normal in vivo migration patterns. This af-
fords the opportunity to examine the in vivo responses of
transduced, naïve or effector T cells following ex vivo gene
transfer. Limitations in previous studies of in vivo adeno-
viral transduction have been the poor stability of adenovi-
ral transduction in dividing cells and the induction of
cytotoxic immune responses to adenoviral gene products.
We observed no decrement in GFP expression by adop-
tively transferred cells as long as 4 days following transfer
(data not shown), but have not yet examined later time
points. Wan et al. reported accelerated loss of Ad-trans-
duced cells relative to controls via an immune-mediated
mechanism [15] suggesting limitations for long-term
adoptive transfer studies into immune-competent recipi-
ents. It is unclear at present how immune responses to Ad-
transduced T cells might affect their in vivo function, but
the ability to examine early in vivo responses following
adoptive transfers for even 3–4 days should prove valua-
ble, and transfers into immune-deficient recipients
should facilitate long-term in vivo studies. Further, con-
tinued advances in the development of "gutless" adenovi-
ral vectors that avoid expression of cytotoxic antigenic
targets may alleviate immune clearance problems [22–
24].
Conclusions
The hCAR∆ cyt.CD2 transgenic lines reported here offer
unique properties that will be advantageous for many T
cell transduction studies. These models offer several ad-
vantages over existing approaches for short-term gene de-
livery into primary T cells, principal of which is the
capacity for high-efficiency transduction of T cells in G0 or
G1 of cell cycle. The introduction of the hCAR∆ cyt.CD2
transgene into TCR transgenic lines, such as the DO11.10
model reported here, will provide a powerful system for T
cell developmental studies. Due to their high immuno-
genicity and their extra-chromosomal replication, the cur-
rent adenoviral vectors may not be appropriate for long-
term transduction in-vivo but improvement in vector de-
sign and adoptive transfer into immunodeficient hosts
may facilitate experiments in the future. The development
of newer recombinant adenoviruses containing elements
for epichromosomal replication may alleviate limitations
that prevent more stable in vivo expression in dividing
lymphoid cells derived from hCAR transgenic mice.
Materials and methods
Mice
DO11.10 TCR transgenic mice specific for ovalbumin
peptide residues 323–339 (OVA323-339) and restricted
by I-Ad[20] were backcrossed onto BALB/cJ background
(>16 generations). Mice were screened for TCR transgene
expression by two-color flow cytometric analysis of pe-
ripheral blood lymphocytes stained with anti-CD4 and
the anti-DO11.10 TCR mAb, KJ1-26 [25]. hCAR∆ cyt
transgenic mice were crossed with BALB/c DO11.10 TCR
Tg mice for at least 5 generations and used at 4–6 weeks of
age. BALB/cJ mice were purchased from the Jackson Labo-
ratory (Bar Harbor, ME) and were used at 6–10 weeks of
age. All mice were maintained in a specific pathogen-free
facility at the University of Alabama at Birmingham and
treated according to the Animal Care Guidelines adopted
by this institution.
Antibodies and reagents
The RmcB (anti-hCAR) (ATCC, [26]) and the KJ1-26 mon-
oclonal antibodies (anti-DO11.10 TCR) were purified
from ascites and conjugated with fluorescein isothiocy-
anate (FITC), biotin or phycoerythrin (PE) by Dr. Roger
Lallone (Brookwood Biomedical; Birmingham, AL). Puri-
fied anti-CD3 (17A2), anti-IL-4 (11B11 and BVD6-24G2),
anti-IL-10 (JES5-2A5 and JES5-16E3), anti-IL-12 (C17.8)
and anti-IFN-γ , PE-conjugated anti-CD4 (GK1.5), biotin-
conjugated anti-CD19 (1D3), anti-CD45R/B220 (RA3-
6B2), anti-CD8 (53-6.72), anti-CD25 (7D4) and anti-
CD62L/L-selectin (MEL-14), Cy-Chrome and PE-labeled
streptavidin were purchased from PharMingen (San Di-
ego, CA). Recombinant murine IL-4 and IL-12 were pur-
chased from R&D Systems Inc. (Minneapolis, MN).
Phorbol 12-myristate 13-acetate (PMA) and ionomycin
were purchased from Sigma (St. Louis, MO).
Generation of hCAR∆ cyt transgenic mice
DNA encoding the extracellular and transmembrane do-
main of the hCAR was obtained by PCR amplification of
a human CAR cDNA [9] kindly provided by Dr. Jeffrey
Bergelson, (Children's Hospital of Philadelphia, Philadel-
phia, PA). The forward primer,
5'ACTGACGAATTCAGCCACCATGGCGCTCCTGCTGTG
C3' introduced an EcoRI site and the reverse primer,
5'GTCAGTCCCGGGTCAGTCAGCTACTTTTTACGACAG
CAAAAGAT3' introduced stop codons in three reading
frames and a SmaI site. The resulting fragment (hCAR∆
cyt) was restriction endonuclease digested and subcloned
into the EcoRI/SmaI site of the VA human CD2 mini-gene
containing the human CD2 promoter and 3' LCR [16].
Automated sequencing (Applied Biosystems, Foster City,
CA; University of Alabama at Birmingham Department of
Microbiology sequencing facility) of the entire construct
confirmed its accuracy. A KpnI/XbaI digest liberated the
CD2/hCAR∆ cyt transgene from the vector backbone andBMC Immunology 2002, 3 http://www.biomedcentral.com/1471-2172/3/4
Page 12 of 14
(page number not for citation purposes)
the transgene was subsequently microinjected into ferti-
lized oocytes by the UAB ES/Transgenic facility.
Adenoviruses
Ad5.CMV5.GFP adenovirus, with an improved cytomega-
lovirus promoter (CMV5) expressing enhanced green flu-
orescent protein (GFP), was purchased from Quantum
Biotechnology (Qbiogen, Carlsbad, CA). The
Ad5.UbP.GFP expressing an enhanced GFP under the con-
trol of a human ubiquitin promoter (UbP) [27] was kind-
ly provided by Dr. J. DeGregori (University of Colorado
Health Science Center, Denver, CO). After large-scale pro-
duction, adenoviruses were purified by double cesium
chloride gradient [7], dialyzed in 10% glycerol/10 mM
HEPES/0.5 mM MgCl2 and stored in viral preservation
medium (25% glycerol/5 mM Tris pH8/50 mM NaCl/
0.05% BSA) until use. Viral titers were determined by OD
measurement and limiting dilution analysis of GFP ex-
pression by transduced 293 cells following Quantum's
AdEasy TCID50 protocol.
Flow cytometric analysis
Splenocytes or lymph node cells were stained for flow cy-
tometry with the PE- or biotin-conjugated monoclonal
antibodies indicated in the appropriate figure legends as
previously described [28]. Cells stained with biotinylated
primary antibody were detected with streptavidin-Cy-
Chrome (Pharmingen). GFP expression was detected in
the FL1 channel. For analytical flow cytometry, 10,000
events with forward and side scatter properties of lym-
phocytes were collected on a FACScan flow cytometer and
analyzed using CellQuest® software (Becton Dickinson;
San Diego, CA).
Primary and secondary cell cultures
CD4+ T cells were isolated from spleen and lymph nodes
from DO11.10 TCR ×  hCAR∆ cyt double transgenic mice
by positive sorting using anti-CD4 magnetic beads (Dynal
AS, Oslo, Norway). Greater than 95% of the resulting cells
were CD4 positive and were plated at a ratio of 1:5 with
irradiated BALB/c splenocytes and 5 µg/ml ovalbumin
peptide 323–339. The addition of 50 U/ml IL-12 and 10
µg/ml anti-IL-4 was used to generate cells with a Th1 phe-
notype, while 1000 U/ml IL-4 and 10 µg/ml anti-IL-12
was used to generate cells with a Th2 phenotype [29]. Af-
ter the initial isolation of the naïve CD4+ T cells, cultures
were treated with the above cytokine/antibody cocktail
weekly for three consecutive weeks to ensure complete po-
larization.
Adenoviral transduction
For adenoviral transduction, lymph nodes and spleen
cells were isolated, treated with ACK lysing buffer for 3
min and washed in DMEM/10 mM HEPES (pH 7.2). Cells
(50 ×  106/ml) were incubated with adenovirus at a multi-
plicity of infection (MOI) of 10 in DMEM/10 mM HEPES
at 37°C under 5% CO2 for 30 min with gentle mixing eve-
ry 10 min. The cells were then washed with PBS and cul-
tured in RP10 (RPMI 1640(GIBCO/BRL)/10% FBS
(HyClone)/0.1 mM 2-mercaptoethanol/1% penicillin-
streptomycin) at 37°C/5% CO2 until analysis. For some
experiments, the transduced cells were then activated with
5 µM ionomycin and 50 ng/ml PMA for 4 h or stimulated
for 18 h by immobilized anti-CD3 (pre-coated at 10 µg/
ml in PBS) or 5 µg/ml OVA peptide with antigen-present-
ing cells before analysis.
Cytokines and proliferation assays
CD4+ T cells from DO11.10 TCR ×  hCAR∆ cyt double
transgenic mice (DO11.hCAR∆ cyt) were isolated and
transduced as described above. After 24 h, the GFP posi-
tive and GFP negative fractions of the transduced lym-
phocytes were sorted using a Becton Dickinson
FACSvantage and cultured under Th1 or Th2 polarizing
conditions as described above. For cytokines assays, 1 ×
106 transduced cells were incubated on anti-CD3 coated
plates for 72 h at 37°C/5% CO2. Culture supernatants
were then harvested and an ELISA assay was performed to
measure the production of IL-4, IL-10 and IFN-γ  as previ-
ously described [30]. To assay proliferation, the trans-
duced cells were plated in duplicate in microtiter plates (5
×  105/well) at a ratio of 1:5 with irradiated BALB/c splen-
ocytes and the indicated doses of OVA peptide at 37°C/
5% CO2. After 72 h, 50 µCi/ml [3H]thymidine (Amer-
sham, Piscataway, NJ) was added to the well. Cells were
further incubated for 24 h and harvested. The incorpora-
tion of [3H]thymidine was measured using a LKB-Wallac
(Gaithersburg, MD) scintillation counter.
Adoptive transfers
CD4+ T cells from hCAR∆ cyt transgenic mice were isolat-
ed and transduced as described above. After 24 h in cul-
ture, 5 ×  106 cells were washed in DMEM, resuspended in
100 µl of DMEM and injected in the tail vein of 6 weeks
old BALB/c mice. The mice were sacrificed after 48 h and
the inguinal, axillary, submandibular and mesenteric
lymph nodes, the spleen and the Peyer's patches were iso-
lated. Half of the spleen and lymph nodes were used for
flow cytometric analysis. The remaining tissues were fixed
for 18 h in 4% formalin in PBS, then washed in PBS and
frozen embedded in OCT (Sakura Finetek, Torrance, CA).
Frozen sections of the spleen, lymph nodes and Peyer's
patches were incubated with 10% normal horse serum in
PBS, counterstained with biotin-labeled B220 antibody
followed by PE-labeled streptavidin, analyzed using a
Nikon E800 fluorescent microscope with a SPOT imaging
system (Diagnostic instruments, Sterling Heights, MI) and
counted as previously described [28].BMC Immunology 2002, 3 http://www.biomedcentral.com/1471-2172/3/4
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Statistical analyses
Data from experimental and control groups were evaluat-
ed by the Student t-test. Differences were considered sig-
nificant when p < 0.05.
List of abbreviations
Ad Adenovirus
hCAR human coxsackie/adenovirus receptor
MFI mean fluorescence intensity
MOI multiplicity of infection
OVA ovalbumin
PEV positional effect variegation
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